TABLE 5.
Stratified study of the diagnostic efficacy of circRNA profiling in BC
| Variables | SEN(95% CI) | SPE (95% CI) | PLR (95% CI) | NLR (95% CI) | DOR (95% CI) | AUC |
|---|---|---|---|---|---|---|
| Control type | ||||||
| BC vs Healthy individuals | 0.75 (0.67‐0.81) | 0.74 (0.65‐0.82) | 2.57 (1.62‐4.08) | 0.36 (0.27‐0.48) | 8.33 (4.55‐15.23) | 0.81 |
| BC vs Adjacent noncancer control | 0.62 (0.58‐0.66) | 0.72 (0.68‐0.75) | 1.86 (1.37‐2.51) | 0.57 (0.48‐0.67) | 3.27 (2.04‐5.26) | 0.65 |
| Function of circRNA | ||||||
| Oncogenic circRNAs | 0.70 (0.64‐0.75) | 0.71 (0.65‐0.77) | 2.26 (1.72‐2.97) | 0.45 (0.37‐0.54) | 5.54 (3.50‐8.76) | 0.76 |
| Tumor‐inhibitory circRNAs | 0.62 (0.57‐0.66) | 0.73 (0.69‐0.77) | 1.76 (1.14‐2.71) | 0.60 (0.46‐0.77) | 2.99 (1.49‐5.99) | 0.65 |
Abbreviations: AUC, area under the curve; BC, breast cancer; DOR, diagnostic odds ratio; NLR, negative likelihood ratio; PLR, positive likelihood ratio; SEN, sensitivity; SPE, specificity.